The Pharmaceutical Research and Manufacturers of America (PhRMA) trade body is donating $1 million to fund President-elect ...

Embedded heuristics and decision-making: In pharma, many decisions are guided by both data and heuristics (i.e., rules of ...

Our latest round-up of financings in the digital health category is headed by a $100 million raise of Inceptive, a start-up set up to apply artificial intelligence to the design of new drugs and ...

The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development. Continuous processing keeps the industry grounded in reaching propelled ESG ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a pivotal ...

Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, although it remains to be seen if it will survive under Donald Trump's new administration.

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo. The US regulator has cleared Rytelo ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring for people living with heart failure. Called Digitiva, it combines Eko ...

Artificial intelligence (AI) and omnichannel have come to seem mere buzzwords these days in the life sciences – everyone is talking about them, everyone wants to use them. But without knowledge ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

We knew it was coming, and now it’s close. By the end of 2024, the US Food and Drug Administration (FDA) is expected to formally make reviews by a single institutional review board (sIRB) the ...